XAF1 As a Modifier of P53 Function and Cancer Susceptibility
Emilia M. Pinto,Bonald C. Figueiredo,Wenan Chen,Henrique C. R. Galvao,Maria Nirvana Formiga,Maria Candida B. Fragoso,Patricia Ashton-Prolla,Enilze M. S. F. Ribeiro,Gabriela Felix,Tatiana E. B. Costa,Sharon A. Savage,Meredith Yeager,Edenir Palmero,Sahlua Volc,Hector Salvador,Jose Luis Fuster-Soler,Cinzia Lavarino,Guillermo Chantada,Dominique Vaur,Vicente Odone-Filho,Laurence Brugieres,Tobias Else,Elena M. Stoffel,Kara N. Maxwell,Maria Isabel Achatz,Luis Kowalski,Kelvin C. de Andrade,Alberto Pappo,Eric Letouze,Ana Claudia Latronico,Berenice B. Mendonca,Madson Q. Almeida,Vania B. Brondani,Camila M. Bittar,Emerson W. S. Soares,Carolina Mathias,Cintia R. N. Ramos,Moara Machado,Weiyin Zhou,Kristine Jones,Aurelie Vogt,Payal P. Klincha,Karina M. Santiago,Heloisa Komechen,Mariana M. Paraizo,Ivy Z. S. Parise,Kayla Hamilton,Jinling Wang,Evadnie Rampersaud,Michael R. Clay,Andrew J. Murphy,Enzo Lalli,Kim E. Nichols,Raul C. Ribeiro,Carlos Rodriguez-Galindo,Marta Korbonits,Jinghui Zhang,Mark G. Thomas,Jon P. Connelly,Shondra Pruett-Miller,Yoan Diekmann,Geoffrey Neale,Gang Wu,Gerard P. Zambetti
DOI: https://doi.org/10.1126/sciadv.aba3231
IF: 13.6
2020-01-01
Science Advances
Abstract:Cancer risk is highly variable in carriers of the common TP53-R337H founder allele, possibly due to the influence of modifier genes. Whole-genome sequencing identified a variant in the tumor suppressor XAF1 (E134*/Glu134Ter/rs146752602) in a subset of R337H carriers. Haplotype-defining variants were verified in 203 patients with cancer, 582 relatives, and 42,438 newborns. The compound mutant haplotype was enriched in patients with cancer, conferring risk for sarcoma (P = 0.003) and subsequent malignancies (P = 0.006). Functional analyses demonstrated that wild-type XAF1 enhances transactivation of wild-type and hypomorphic TP53 variants, whereas XAF1-E134* is markedly attenuated in this activity. We propose that cosegregation of XAF1-E134* and TP53-R337H mutations leads to a more aggressive cancer phenotype than TP53-R337H alone, with implications for genetic counseling and clinical management of hypomorphic TP53 mutant carriers.